PDUFA IV Fix For FDA Performance On Standard Reviews Advocated By BIO
Executive Summary
Prescription Drug User Fee Act negotiations should address the discrepancy in FDA performance on approval times for standard and priority review applications, Biotechnology Industry Organization's Amit Sachdev said
You may also be interested in...
PDUFA IV Negotiations Underway With FDA, Industry Working In Harmony
PhRMA will pursue earlier postmarketing commitment negotiations with FDA as part of a limited industry agenda for the third reauthorization of the Prescription Drug User Fee Act
PDUFA IV Negotiations Underway With FDA, Industry Working In Harmony
PhRMA will pursue earlier postmarketing commitment negotiations with FDA as part of a limited industry agenda for the third reauthorization of the Prescription Drug User Fee Act
Key To First-Cycle Approval Is To Meet Early And Often, Consultants Tell FDA
An independent analysis of FDA's first-cycle review performance provides support for the agency's request for additional funding for pre-submission meetings